| Chronic rhinosinusitis with multiple nasal polyps
Tezspire vs Xolair
Side-by-side clinical, coverage, and cost comparison for chronic rhinosinusitis with multiple nasal polyps.Deep comparison between: Tezspire vs Xolair with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsXolair has a higher rate of injection site reactions vs Tezspire based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Xolair but not Tezspire, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Tezspire
Xolair
At A Glance
SC injection
Every 4 weeks
TSLP blocker
SC injection
Every 2-4 weeks
Anti-IgE antibody
Indications
- Asthma
- Chronic rhinosinusitis with multiple nasal polyps
- Asthma
- Chronic rhinosinusitis with multiple nasal polyps
- IgE-mediated food allergy
- Chronic Spontaneous Urticaria
Dosing
Asthma, Chronic rhinosinusitis with multiple nasal polyps 210 mg administered subcutaneously once every 4 weeks.
Asthma 75 to 375 mg SC every 2 or 4 weeks based on serum total IgE level (IU/mL) measured before the start of treatment and body weight (kg).
Chronic rhinosinusitis with multiple nasal polyps 75 to 600 mg SC every 2 or 4 weeks based on serum total IgE level (IU/mL) measured before the start of treatment and body weight (kg).
IgE-mediated food allergy 75 to 600 mg SC every 2 or 4 weeks based on serum total IgE level (IU/mL) measured before the start of treatment and body weight (kg).
Chronic Spontaneous Urticaria 150 or 300 mg SC every 4 weeks; dosing is not dependent on serum IgE level or body weight.
Contraindications
- Known hypersensitivity to tezepelumab-ekko or any of its excipients
- Severe hypersensitivity reaction to omalizumab or any ingredient of XOLAIR
Adverse Reactions
Most common (>=3%) Nasopharyngitis, upper respiratory tract infection, pharyngitis, arthralgia, back pain, epistaxis, influenza, injection site reaction
Serious Serious cardiac adverse events (incidence rate 1.08 per 100 patient-years in TEZSPIRE vs 0.21 in placebo in long-term extension trial)
Postmarketing Anaphylaxis
Most common (>=1%) Arthralgia, pain, injection site reactions, headache, fatigue, dizziness, pruritus, nasopharyngitis, sinusitis, upper respiratory tract infection, dermatitis, earache
Serious Anaphylaxis, malignancies, cardiovascular and cerebrovascular events
Postmarketing Anaphylaxis, eosinophilic conditions, fever with arthralgia and rash (serum sickness-like), severe thrombocytopenia, hair loss
Pharmacology
TSLP blocker; tezepelumab-ekko is a human monoclonal antibody (IgG2lambda) that binds human thymic stromal lymphopoietin (TSLP) and blocks its interaction with the heterodimeric TSLP receptor, thereby reducing inflammatory biomarkers including blood eosinophils, IgE, FeNO, IL-5, and IL-13.
Omalizumab is a recombinant humanized IgG1 monoclonal antibody that inhibits the binding of IgE to high-affinity IgE receptors (FceRI) on mast cells, basophils, and dendritic cells, resulting in FceRI down-regulation and reduction of IgE-mediated inflammatory responses; in CSU, omalizumab binds to IgE and lowers free IgE levels with down-regulation of IgE receptors, though the exact mechanism by which this results in CSU symptom improvement is unknown.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Tezspire
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Xolair
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (11/12) · Qty limit (11/12)
UnitedHealthcare
Tezspire
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (4/8) · Qty limit (0/8)
Xolair
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (8/8) · Qty limit (6/8)
Humana
Tezspire
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Xolair
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Asthma - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Asthma - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
TezspireView full Tezspire profile
XolairView full Xolair profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.